HENNEMAN JOHN B III 4

What Happened
John B. Henneman III, a director of Anika Therapeutics, was granted 10,402 restricted stock units (RSUs) on June 18, 2026. The award was reported as an acquisition (award/grant) at a $0.00 per-unit price (no cash paid). The RSUs represent a contingent right to one share each and will vest in full on the earlier of the Company's 2027 annual meeting or June 18, 2027.

Key Details

• Transaction date: 2026-06-18; reported on Form 4 filed 2026-06-23.
• Security: 10,402 RSUs granted; reported price $0.00 (award).
• Vesting: RSUs vest in full by the earlier of the 2027 annual meeting or June 18, 2027 (per footnote).
• Shares owned after transaction: not specified in the provided filing.
• Timeliness: Filing appears to have been reported 3 business days after the grant (filed 6/23 for a 6/18 transaction), which is later than the standard 2-business-day Form 4 reporting window.

Context
RSUs are a form of equity compensation that convert into shares only upon vesting; they are not an immediate open‑market purchase or sale. Grants to directors are commonly part of routine compensation and do not by themselves indicate the director is buying or selling stock. Note the later filing may warrant attention to reporting timeliness, but the transaction itself is an issued award, not a sale or purchase.